Full Press Release Details
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases.
ARGX
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases
Key Takeaway: argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis